Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YSP Good Proxy to Domestic Drug Industry (Malaysia)

This article was originally published in PharmAsia News

Executive Summary

According to estimates by Kenanga Investment Bank Research, YSP Southeast Asia Holding may be a legitimate proxy for the Malaysian pharmaceutical industry. In the first half of 2007, the company saw its pretax profits double, thanks to a 15 percent increase in sales, most of which came from exports. The majority of YSP's products are produced in Malaysia, at a facility in Selangor. It also boasts several distribution centers around the country. As a subsidiary of Yung Shin Pharmaceutical Industries in Taiwan, YSP has greater access to research and development then many of its competitors. These factors will allow YSP to further increase its exports, providing access to a market beyond Malaysia's population of 24.8 million. The company plans to expand exports throughout its distribution network in the Philippines, Singapore, Vietnam, Myanmar, and Cambodia. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065684

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel